TAA06 is a CAR T-cell injection targeting B7-H3 and its efficacy and safety are tested in a phase I trial, that is currently recruiting, in patients with CRC and other advanced solid malignancies (NCT05190185). Here, CD276 is linked to colorectal carcinoma.